CoChat

Inactivated COVID-19 vaccine BBV152/COVAXIN effectively neutralizes recently emerged B.1.1.7 variant of SARS-CoV-2

Open access
Sapkal, Gajanan N, Yadav, Pragya D, Ella, Raches, Deshpande, Gururaj R, Sahay, Rima R, Gupta, Nivedita, Vadrevu, Krishna Mohan, Abraham, Priya, Panda, Samiran, Bhargava, Balram · 2021 · Journal of Travel Medicine
Cited by 121

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

The rapid surge of SARS-CoV-2 cases due to the ‘variant of concern (VOC) 202 012/01’, also known as lineage B.1.1.7 or 20B/501Y.V1 in the UK,1 in December 2020, raised concerns in several countries due to its high transmissibility. Many of these countries had direct flights to and from the UK. Since the identification of the new variants of Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in the UK and South Africa,2 health experts have also expressed their concerns about their potential implications pertaining to vaccine efficacy. The root of such concerns was grounded in the structure of the SARS-CoV-2 variant, VOC-202012/01, which came to the centre stage of discussion due to its greater transmissibility in humans compared with the other known SARS-CoV-2 lineages. This variant carries 17 mutations in the genome, 8 of which have been found in spike receptor-binding domain (RBD), mediating the attachment of the virus to the angiotensin-converting enzyme 2 (ACE2) receptor on the surface of human cells.2 One of these mutations, N501Y, at position 501, has asparagine (N) replaced with tyrosine (Y) and has been identified to increase the binding affinity of SARS-CoV-2 to human and murine ACE2.2 Therefore, it appeared that the majority of the vaccine candidates, being either recombinant or specifically targeting the single epitope of the original D614G ancestral spike sequence, might not be able to generate an efficient immune response against the new variants. Here, we successfully isolated and characterized the hCoV-19/India/20203522 SARS-CoV-2 (VOC) 202 012/01 from UK returnees in India with all signature mutations of the UK variant.3 The VOC 202012/01 hallmarks belonged to the GR clade of the viral isolates recovered from the UK returnees coming back to India.3 The method used by us for virus isolation and culture from the clinical specimens of COVID-19 are described elsewhere.4 The SARS-CoV-2 strain (NIV-2020-770) used in developing the BBV152 vaccine was retrieved from tourists who arrived in New Delhi, India.4,5 The virus isolation was performed in the ‘Vero CCL-81’ cells and the genome sequence was deposited in the GISAID (EPI_ISL_420545). The BBV152 vaccine candidate strain is located in the (G clade), containing the Asp614Gly mutation, which is characterized by aspartic acid to glycine shift at the amino acid (AA) position 614 of the spike protein. This was used for PRNT50 assay in the present investigation.4 Earlier, we reported the development of an inactivated whole-virion SARS-CoV-2 vaccine BBV152, which elicited a remarkable neutralizing antibody response in Phase I clinical trial against hCoV-19/India/2020770 (homologous), and two heterologous strains from the unclassified cluster, namely, hCoV-19/India/2020Q111 and hCoV-19/India/2020Q100.6 The hCoV-19/India/2020Q111 and hCoV-19/India/2020Q100 virus isolate strains contain the L3606F mutation, where leucine to phenylalanine shifted at AA position 3606 of the ORF1ab5 have been observed. (A) Neutralizing antibody response of BBV152/COVAXIN vaccinated sera against SARS CoV-2 strains: neutralizing antibody titres (PRNT50 value) of vaccinees’sera against hCoV-19/India/2020770 (homologous Asp614Gly mutation G clade), hCoV-19/India/20203522 (heterologous UK variant ‘(VOC) 202 012/01’ hallmarks belonged to GR clade) and hCoV-19/India/2020Q111 (heterologous unclassified cluster with L3606F mutation). The bar represents the geometric mean and standard deviation (SD) of the respective group titres. Non-parametric Kruskal–Wallis test was used for the comparison of the PRNT50 values from different groups. The P values above 0.05 were considered non-significant and are marked on the figure (ns, non-significant). (B) Details of SARS-CoV-2 strains used for plaque reduction neutralization test with respective mutations. (C) Comparison of PRNT50 value of each vaccine recipient’s sera with three strains of SARS CoV-2: neutralizing antibody titres (PRNT50 value) of each vaccinee’s sera against hCoV-19/India/2020770 (homologous Asp614Gly mutation G clade), hCoV-19/India/20203522 (heterologous UK variant ‘(VOC) 202 012/01’ hallmarks belonged to GR clade) and hCoV-19/India/2020Q111 (heterologous unclassified cluster with L3606F mutation). The bar represents the mean and SD of the respective sera. In Phase II clinical trial, following two dose immunization schedule at Days 0 and 28 with 6 and 3 μg antigen with imidazoquinoline (TLR7/TLR8 agonist adsorbed on aluminium hydroxide gel), the vaccine candidate showed noteworthy results in plaque reduction neutralization test (PRNT50)-based assay, with the seroconversion rates of neutralizing antibodies being 98.6%.7 Here, we present the NAb titres (PRNT50) of sera collected (4 weeks after the second dose) from 38 vaccine recipients, who received the BBV152 vaccine candidate in Phase II trial7 to underline the immunogenicity of the BBV152 vaccine candidate against SARS-CoV-2 UK variant with (VOC) 202 012/01 hallma

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/jtm/taab051

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 121

Metadata

Authors
Sapkal, G. N., Yadav, P. D., Ella, R., Deshpande, G. R., Sahay, R. R., Gupta, N., Vadrevu, K. M., Abraham, P., Panda, S., & Bhargava, B.
Venue
Journal of Travel Medicine
Published
2021-03-27
Volume
28
Issue
4
ISSN
  • 1195-1982 (ISSN-L)
  • 1708-8305
OpenAlex
W3141123178
Cited by
121
References
4
FWCI
8.66
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Inactivated COVID-19 vaccine BBV152/COVAXIN effectively neutralizes recently emerged B.1.1.7 variant of SARS-CoV-2. https://app.cochat.ai/papers/10.1093/jtm/taab051
The paper
Sapkal, G. N., Yadav, P. D., Ella, R., Deshpande, G. R., Sahay, R. R., Gupta, N., Vadrevu, K. M., Abraham, P., Panda, S., & Bhargava, B. (2021). Inactivated COVID-19 vaccine BBV152/COVAXIN effectively neutralizes recently emerged B.1.1.7 variant of SARS-CoV-2. Journal of Travel Medicine. https://doi.org/10.1093/jtm/taab051

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.